BACKGROUND: Surfactant protein D (SP-D) is a collection that plays important roles in modulating host defense functions and maintaining phospholipid homeostasis in the lung. The aim of current study was to characterize comparatively the SP-D response in bronchoalveolar lavage (BAL) and serum in three murine models of lung injury, using a validated ELISA technology for estimation of SP-D levels. METHODS: Mice were exposed to lipopolysaccharide, bleomycin, or Pneumocystis carinii (Pc) and sacrificed at different time points. RESULTS: In lipopolysaccharide-challenged mice, the level of SP-D in BAL increased within 6 h, peaked at 51 h (4,518 ng/ml), and returned to base level at 99 h (612 ng/ml). Serum levels of SP-D increased immediately (8.6 ng/ml), peaked at 51 h (16 ng/ml), and returned to base levels at 99 h (3.8 ng/ml). In a subacute bleomycin inflammation model, SP-D levels were 4,625 and 367 ng/ml in BAL and serum, respectively, 8 days after exposure. In a chronic Pc inflammation model, the highest level of SP-D was observed 6 weeks after inoculation, with BAL and serum levels of 1,868 and 335 ng/ml, respectively. CONCLUSIONS: We conclude that serum levels of SP-D increase during lung injury, with a sustained increment during chronic inflammation compared with acute inflammation. A quick upregulation of SP-D in serum in response to acute airway inflammation supports the notion that SP-D translocates from the airways into the vascular system, in favor of being synthesized systemically. The study also confirms the concept of using increased SP-D serum levels as a biomarker of especially chronic airway inflammation.
BACKGROUND:Surfactant protein D (SP-D) is a collection that plays important roles in modulating host defense functions and maintaining phospholipid homeostasis in the lung. The aim of current study was to characterize comparatively the SP-D response in bronchoalveolar lavage (BAL) and serum in three murine models of lung injury, using a validated ELISA technology for estimation of SP-D levels. METHODS:Mice were exposed to lipopolysaccharide, bleomycin, or Pneumocystis carinii (Pc) and sacrificed at different time points. RESULTS: In lipopolysaccharide-challenged mice, the level of SP-D in BAL increased within 6 h, peaked at 51 h (4,518 ng/ml), and returned to base level at 99 h (612 ng/ml). Serum levels of SP-D increased immediately (8.6 ng/ml), peaked at 51 h (16 ng/ml), and returned to base levels at 99 h (3.8 ng/ml). In a subacute bleomycininflammation model, SP-D levels were 4,625 and 367 ng/ml in BAL and serum, respectively, 8 days after exposure. In a chronic Pcinflammation model, the highest level of SP-D was observed 6 weeks after inoculation, with BAL and serum levels of 1,868 and 335 ng/ml, respectively. CONCLUSIONS: We conclude that serum levels of SP-D increase during lung injury, with a sustained increment during chronic inflammation compared with acute inflammation. A quick upregulation of SP-D in serum in response to acute airway inflammation supports the notion that SP-D translocates from the airways into the vascular system, in favor of being synthesized systemically. The study also confirms the concept of using increased SP-D serum levels as a biomarker of especially chronic airway inflammation.
Authors: Masaki Fujita; John M Shannon; Hiroshi Ouchi; Dennis R Voelker; Yoichi Nakanishi; Robert J Mason Journal: Cytokine Date: 2005-07-07 Impact factor: 3.861
Authors: John Casey; Jennifer Kaplan; Elena N Atochina-Vasserman; Andrew J Gow; Helchem Kadire; Yaniv Tomer; James H Fisher; Samuel Hawgood; Rashmin C Savani; Michael F Beers Journal: Am J Respir Crit Care Med Date: 2005-06-30 Impact factor: 21.405
Authors: Paul S Kingma; Liqian Zhang; Machiko Ikegami; Kevan Hartshorn; Francis X McCormack; Jeffrey A Whitsett Journal: J Biol Chem Date: 2006-06-20 Impact factor: 5.157
Authors: Elena N Atochina-Vasserman; Andrew J Gow; Helen Abramova; Chang-Jiang Guo; Yaniv Tomer; Angela M Preston; James M Beck; Michael F Beers Journal: J Immunol Date: 2009-02-15 Impact factor: 5.422
Authors: D A Lomas; E K Silverman; L D Edwards; N W Locantore; B E Miller; D H Horstman; R Tal-Singer Journal: Eur Respir J Date: 2009-01-22 Impact factor: 16.671
Authors: Chang-Jiang Guo; Elena N Atochina-Vasserman; Elena Abramova; Joseph P Foley; Aisha Zaman; Erika Crouch; Michael F Beers; Rashmin C Savani; Andrew J Gow Journal: PLoS Biol Date: 2008-11-11 Impact factor: 8.029
Authors: Andreia Z Chignalia; Stephen M Vogel; Albert B Reynolds; Dolly Mehta; Randal O Dull; Richard D Minshall; Asrar B Malik; Yuru Liu Journal: Am J Pathol Date: 2015-03-13 Impact factor: 4.307
Authors: Arindam Chakrabarti; Allen Nguyen; Margaret M Newhams; Maikke B Ohlson; Xiaoying Yang; Sheila Ulufatu; Shannon Liu; Summer Park; Min Xu; Jenny Jiang; Wendy G Halpern; Veronica G Anania; Jacqueline M McBride; Carrie M Rosenberger; Adrienne G Randolph Journal: Pediatr Pulmonol Date: 2021-12-07
Authors: Jeffrey E Gotts; Lauren Chun; Jason Abbott; Xiaohui Fang; Naoki Takasaka; Stephen L Nishimura; Matthew L Springer; Suzaynn F Schick; Carolyn S Calfee; Michael A Matthay Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-03-15 Impact factor: 5.464
Authors: Jens-Ulrik S Jensen; Theis S Itenov; Katrin M Thormar; Lars Hein; Thomas T Mohr; Mads H Andersen; Jesper Løken; Hamid Tousi; Bettina Lundgren; Hans Christian Boesen; Maria E Johansen; Sisse R Ostrowski; Pär I Johansson; Jesper Grarup; Jørgen Vestbo; Jens D Lundgren Journal: Ann Intensive Care Date: 2016-11-21 Impact factor: 6.925
Authors: Rose-Marie A Mackay; Christopher L Grainge; Laurie C Lau; Clair Barber; Howard W Clark; Peter H Howarth Journal: Chest Date: 2016-01-13 Impact factor: 9.410
Authors: Kate L Lambertsen; Kamilla Østergaard; Bettina H Clausen; Søren Hansen; Jan Stenvang; Stine B Thorsen; Michael Meldgaard; Bjarne W Kristensen; Pernille B Hansen; Grith L Sorensen; Bente Finsen Journal: J Neuroinflammation Date: 2014-07-19 Impact factor: 8.322